FDA aligned on single-arm Phase 3 study to support potential accelerated and full approvalOn track to dose first patient in Phase 3 trial in ...

Families of rare disease patients appeal to PM Modi and Health Minister for increased treatment funding support.

LONDON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced positive feedback from its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting its ...

The FDA has offered positive feedback on possible paths forward for accelerated or traditional approval of FLT201 using data from a single-arm study.

AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...

PLX READ THE FULL PLX RESEARCH REPORT Reasons To Own / A Compelling Idea for 2025 Protalix Biotherapeutics, Inc. (NYSE:PLX) ...

Syncona Ltd (”Syncona”), a leading life science investor focused on creating, building and scaling a portfolio of global leaders in life science, today issues its quarterly update covering the period ...

The global enzyme replacement therapy market size was valued at USD 10.12 billion in 2024 and is projected to grow from USD 11.35 billion in 2025 to reach USD 21.29 billion by 2033, exhibiting a CAGR ...

Syncona Ltd on Wednesday said portfolio company Achilles Therapeutics PLC is planning to return capital to shareholders though a members' solvent voluntary liquidation. The London-based investor in ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Major Cause of Inflammatory ...

Gain Therapeutics, Inc.’s GANX share price has surged by 10.41%, which has investors questioning if this is right time to sell.

Leading global drugmakers such as MSD Pharmaceuticals, Novartis, AstraZeneca, and Pfizer stand to benefit as it opens new ...